Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Data from clinical studies of ALD-201 and ALD-301 will be presented at the American Heart Association Scientific Sessions 2009 in Orlando, Florida.

Aldagen, Inc. announced that data from clinical studies of ALD-201 and ALD-301 will be presented at the American Heart Association Scientific Sessions 2009 in Orlando, Florida.ALD-201 and ALD-301 are regenerative cell therapies being developed as treatments for ischemic heart failure and critical limb ischemia, respectively.

ALD-201

• Session Title: Heart Failure: Cell and Gene Based Therapies I
• Abstract Title: First In Man Transendocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Cells in Heart Failure Patients (FOCUS-Bright)
• Oral Session, Presenter: Emerson C. Perin, MD, PhD, FACC, Director,New Cardiovascular Interventional Technology; Director, Clinical Researchfor Cardiovascular Medicine, Texas Heart Institute
• Date/Time: Tuesday, November 17, 2009, 10:00 am ET
• Location: Room W102

ALD-301

• Session Title: Stem/Progenitor Cells: Translational Studies
• Abstract Title: CLI-Bright: A Phase I Randomized Blinded Clinical, Trial Comparing the Effect of Intramuscular Injection of Autologous Bone, Marrow Derived Aldehyde Dehydrogenase Bright Cells and Mononuclear Stem,Cells in Patients With Critical Limb Ischemia,Poster Session
• Date/Time: Sunday, November 15, 2009, 9:30-11:00 am ET
• Location: Poster Hall A2-A3, Core 7

Source: Aldagen, Inc.

You can discuss about Cardiology and its products & services in the Cardiology Group.